4//SEC Filing
Sethuraman Natarajan 4
Accession 0001689375-24-000067
CIK 0001689375other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:24 PM ET
Size
8.7 KB
Accession
0001689375-24-000067
Insider Transaction Report
Form 4
Sethuraman Natarajan
President, Research & Develop.
Transactions
- Sale
Common Stock
2024-11-29$20.00/sh−100$2,000→ 160,788 total - Sale
Common Stock
2024-12-02$20.26/sh−4,088$82,834→ 156,700 total - Sale
Common Stock
2024-12-03$20.15/sh−11,703$235,786→ 144,997 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Entrada Therapeutics, Inc.
CIK 0001689375
Entity typeother
Related Parties
1- filerCIK 0001873394
Filing Metadata
- Form type
- 4
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 5:24 PM ET
- Size
- 8.7 KB